Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells
Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells
复制标题
Embelin 通过直接诱导癌细胞凋亡和间接限制 IL-6 相关炎症和免疫抑制细胞来抑制胰腺癌进展。
DOI：
10.1016/j.canlet.2014.08.011
复制
发表时间：
2014-11-28
期刊：
影响因子：
9.7
通讯作者：
Zhang, Rongxin
中科院分区：
文献类型：
--
作者：
Peng, Meiyu;Huang, Bingqing;Zhang, Rongxin
胰腺癌是一种侵袭性恶性肿瘤，对常规化疗无反应。本研究旨在探讨恩贝林对胰腺癌的抗炎和抗肿瘤作用。Embelin通过抑制STAT 3和激活p53信号通路，抑制细胞侵袭、增殖并诱导细胞凋亡。Embelin通过抑制IL-6的分泌，显著降低胰腺癌细胞的体内致瘤性，这与炎症细胞和免疫抑制细胞、IL-17 A（+）Th 17、GM-CSF+ Th、MDSCs和Treg的减少有关。此外，Embelin降低IL-6诱导的STAT 3磷酸化。总之，恩贝林代表了胰腺癌临床治疗的新型治疗药物候选者。(C)2014爱思唯尔爱尔兰有限公司版权所有。
Pancreatic cancer is an aggressive malignancy and unresponsive to conventional chemotherapies. Here, the anti-inflammatory and anti-tumor effects of embelin on pancreatic cancer were investigated. Embelin significantly attenuated cells invasion, proliferation and induced apoptosis through inhibition of STAT3 and activation of p53 signaling pathways. Embelin substantially reduced the tumorigenicity of pancreatic cancer cells in vivo, which was associated with reduced inflammatory cells and immune suppressive cells, IL-17A(+) Th17, GM-CSF+ Th, MDSCs and Treg, through inhibition of IL-6 secretion. Moreover, embelin decrease IL-6-induced STAT3 phosphorylation. In summary, embelin represents a novel therapeutic drug candidate for the clinical treatment of pancreatic cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.